• Careers
  • News
  • Publications
  • Contact Us
  • Company
    • About Us
    • Management Team
    • Board of Directors
    • Collaborations
    • Careers
    • Contact Us
  • Therapeutic Areas
    • Oncology
    • Publications
  • Programs
    • Pipeline
    • mTORC1/2 inhibitor Sapanisertib
    • SYK Inhibitor Mivavotinib
    • Preclinical Programs
  • Clinical Trials
    • Clinical Trials Overview
    • Expanded Access
  • Investors
    • Corporate Profile
    • Press Releases
    • Event & Presentations
    • Stock Information
    • Financial Information
      • Overview
      • SEC Filings
      • Ownership Summary
    • Analyst Coverage
    • Corporate Governance
      • Highlights
      • Board of Directors
      • Management Team
      • Committee Composition
    • Shareholder Services
      • Investor FAQs
      • E-mail Alerts
    • Proxy & Annual Report
    • Contact Us
  • Careers
  • News
  • Publications
  • Contact Us

Targeting cancer, differently.

Our biomarker-driven approach will
redefine cancer treatment.

Learn More

Targeting cancer, differently.

Our biomarker-driven approach will
redefine cancer treatment.

Learn More

Targeting cancer, differently.

Our biomarker-driven approach will
redefine cancer treatment.

Learn More

Development Pipeline

Calithera Biosciences is a clinical-stage, precision oncology biopharmaceutical company developing targeted therapies to redefine treatment for biomarker-specific patient populations.

Learn More

Development Pipeline

Calithera is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted, small molecule therapies that disrupt cellular metabolic pathways to preferentially block tumor cell growth and enhance immune-cell activity.

Learn More

Culture

Therapeutic Areas

Recent News

August 8, 2022

Calithera Biosciences to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022

July 13, 2022

Calithera Biosciences Shares Progress in Sapanisertib and Mivavotinib Clinical Programs at Upcoming Lung Cancer and Lymphoma Conferences

July 6, 2022

Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Sapanisertib in Relapsed/Refractory NRF2 (NFE2L2)-Mutated Squamous Non-Small Cell Lung Cancer

June 23, 2022

Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Mivavotinib in Relapsed/Refractory non-GCB (ABC) Diffuse Large B-Cell Lymphoma

June 14, 2022

Calithera Biosciences Announces 1-for-20 Reverse Stock Split

View All
Company
  • About Us
  • Management Team
  • Board of Directors
  • Collaborations
  • Careers
  • Contact Us
Therapeutic Areas
  • Oncology
  • Publications
Programs
  • Pipeline
  • mTORC1/2 inhibitor Sapanisertib
  • SYK Inhibitor Mivavotinib
  • Preclinical Programs
Clinical Trials
  • Clinical Trial Overview
  • Expanded Access
Investors
  • Corporate Profile
  • Press Release
  • Events & Presentations
  • Stock Information
  • Financial Information
  • Analyst Coverage
  • Corporate Governance
  • Shareholder Services
  • Proxy & Annual Report
  • Contact Us
© 2022 Calithera Biosciences, Inc. All rights reserved.
ETHICS & COMPLIANCEPRIVACY POLICYLEGAL TERMS OF USE
  • Contact Us
  • News
CALITHERA® and the Calithera logos are trademarks or registered trademarks of Calithera Biosciences, Inc.
CALITHERA® and the Calithera logos are trademarks or registered trademarks of Calithera Biosciences, Inc.